Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04929236 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
A Phase 3 study of Pediatric Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by Octapharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
- 6
- Study locations
NCT04929236 is a Phase 3 study of Pediatric Chronic Inflammatory Demyelinating Polyneuropathy that is actively recruiting participants, run by Octapharma. The registered enrollment target is 30 participants. The trial reports 6 study locations across 6 states.
The verdict
NCT04929236, a Phase 3 study of Pediatric Chronic Inflammatory Demyelinating Polyneuropathy, is actively recruiting participants, sponsored by Octapharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
- 6
- Study locations
Study Summary
Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Conditions Studied
Interventions
- DRUG Panzyga
Study Locations (6)
Alabama
- Octapharma Research Site - Birmingham
California
- Octapharma Research Site - Orange
Kentucky
- Octapharma Research Site - Louisville
Pennsylvania
- Octapharma Research Site - Philadelphia
Texas
- Octapharma Research Site - Houston
Virginia
- Octapharma Research Site - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-10-01 |
| Est. Completion | 2026-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04929236
The ClinicalTrials.gov registry entry for NCT04929236 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pediatric Chronic Inflammatory Demyelinating Polyneuropathy appearing as the primary indexed condition, and to 1 intervention - of which Panzyga is the first listed.
NCT04929236 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Alabama, California, Kentucky.
Frequently Asked Questions
What is clinical trial NCT04929236 about?
NCT04929236 is a clinical study titled "Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients". Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
What is the current status of trial NCT04929236?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2023-10-01. Estimated completion is 2026-06.
What conditions does trial NCT04929236 study?
This clinical trial studies the following conditions: Pediatric Chronic Inflammatory Demyelinating Polyneuropathy.
What interventions are being tested in trial NCT04929236?
The interventions under investigation include: Panzyga (DRUG).
Who is sponsoring clinical trial NCT04929236?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04929236 being conducted?
This trial has 6 study locations across Alabama, California, Kentucky, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.